2Klugman KP, Low DE, Metlay J, et al. Community -acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities [ J ]. Int J Antimicrob Agents, 2004,24 (5): 411.
3Mandell LA, Bartlett JG, Dowell JF, et al. Update of practice guidelines for the management of community - acquired pneumonia in immunocompetent adults [ J ]. Clin Infect Dis,2003,37(11) :1 405.
4Niederman MS, Mandell LA, Anuzeto A, et al. Guidelines for the management of adults with community - acquired pneumonia [J]. Am J Respir Crit Care Med,2001,163(7 ) : 1 730.
5Gould IM. BTS guidelines on CAP[J]. Thorax,2002,57(7):657.
6Reinert RR, Ringelstein A, van-der-Linden M, et al. Molecular epidemiology of macrolide-resistant streptococcus pneumoniae isolates in Europe[J]. J Clin Microbiol ,2005 ,43 ( 3 ) : 1 294.
7Wierzbowski AK, Swedlo D, Boyd D, et al. Molecular epidemiology and prevalence of macrolide efflux genes mef(A)and mef(E) in streptococcus pneumoniae obtained in Canada from 1997 to 2002[ J]. Antimicrob Agents and Chemotherapy,2005,49(3): 1 257.
8Brown SD, Farrell DJ, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of streptococcus pneumoniae collected during the 2000 ～2001 PROTEKT US study [ J]. J Clin Microbiol, 2004,42(11) :4 980.
9Maglio D, Capitano B, Banevicius MA, et al. Efficacy of clarithromycin against streptococcus pneumoniae expressing mef (A) - mediated resistance[J]. Int J Antimicrob Agents ,2004,23(5) :498.
10File TM Jr, Tan JS. International guidelines for the treatment of community- acquired pneumonia in adults: the role of macrolides[ J]. Drugs ,2003,63(2): 181.
